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Background: Chronic obstructive pulmonary disease (COPD) is influenced by environmental and genetic factors.
An important fraction of COPD cases harbor a major genetic determinant, inherited ZZ (Glu342Lys) α1-antitrypsin
deficiency (AATD). A study was undertaken to investigate gene expression patterns in end-stage COPD lungs from
patients with and without AATD.
Methods: Explanted lungs of end-stage ZZ AATD-related (treated and non-treated with AAT augmentation
therapy) and “normal” MM COPD, and liver biopsies from patients suffering from liver cirrhosis with and without ZZ
AATD were used for gene expression analysis by Affymetrix microarrays or RT-PCR.
Results: A total of 162 genes were found to be differentially expressed (p-value≤ 0.05 and |FC|≥ 2) between MM
and ZZ COPD patients. Of those, 134 gene sets were up-regulated and 28 were down-regulated in ZZ relative to
MM lung tissue. A subgroup of genes, zinc finger protein 165, snail homolog 1 (Drosophila) (SNAI1), and
Krüppel-like transcription factors (KLFs) 4 (gut), 9 and 10, perfectly segregated ZZ and MM COPD patients. The
higher expression of KLF 9 and KLF10 has been verified in the replication cohort with AATD-related end-stage lung
emphysema and liver cirrhosis. Furthermore, higher expression of KLF9, SNAI1 and DEFA1 was found in ZZ COPD
lungs without augmentation therapy relative to MM COPD or ZZ COPD with augmentation therapy.
Conclusions: These results reveal the involvement of transcriptional regulators of the zinc-finger family in COPD
pathogenesis and provide deeper insight into the pathophysiological mechanisms of COPD with and without
AATD.
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Chronic obstructive pulmonary disease (COPD) includes
a broad spectrum of respiratory symptoms and histo-
pathological changes with varying degrees of severity,
and it is typically diagnosed late in the course of disease
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reproduction in any medium, provided the or[1,2]. Different inflammatory cells (macrophages, neutro-
phils, CD8+ T lymphocytes) and several interrelated pro-
cesses, such as chronic inflammation per se, proteinase/
anti-proteinase imbalance, oxidative stress, apoptosis
and replenishment of structural cells, are thought to
contribute to the pathogenesis of COPD [3]. Given this
complexity of COPD, the identification of biological
markers of disease susceptibility and/or progression is of
great importance [4]. DNA microarrays have been
proven to be a powerful tool capable of biomarker dis-
covery for various disease entities. Previous studies used
this approach to characterize global gene expression pat-
terns from lung tissue of patients with COPD, and tol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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these gene expression patterns have produced differing
results likely due to differences in the types of patients
enrolled and due to inherent heterogeneity of COPD.
An important fraction of COPD cases harbor a major
genetic determinant, inherited ZZ (Glu342Lys) α1-
antitrypsin deficiency (AATD). AAT is an acute phase
protein, main inhibitor of neutrophil elastase and a
modulator of host inflammatory responses [5]. It is well
established that the Z variant of AAT forms polymers
and is retained in the endoplasmic reticulum (ER) of the
hepatocytes [6] which leads to markedly impede (up to
90%) levels of the circulating AAT protein. The lack of
AAT predisposes a person to develop early onset, rapidly
progressive COPD where emphysema is a major compo-
nent [7] whereas the accumulation of abnormally folded
AAT protein increases the risk to develop chronic liver
disease. Cirrhosis in ZZ AATD individuals may become
clinically apparent at any age, with the peak incidence
typically occurring in elderly never-smokers who have
survived without developing severe emphysema [8].
In an attempt to further improve our understanding of
the complex molecular basis of AATD-related pathology,
we aimed to investigate gene expression patterns in well
matched end-stage COPD lungs from patients with and
without inherited α1-antitrypsin deficiency (AATD). The
identified genes differently expressed were then validated
in separate groups of ZZ and MM end-stage COPD lung
tissue and biopsies from liver cirrhosis patients using
real time PCR. This strategy was used to confirm the re-
producibility of our findings in different populations,
which increases the probability of results being applic-
able to the wider population of COPD patients.
Methods
Lung tissue
Tissues from explanted lungs of end-stage ZZ AATD-
related COPD (n = 3) and non-AATD, MM COPD
(n = 3) were received from the Biobank in Giessen which
is a part of the EU 6th Framework Programme (Contract
No: LSHM-CT-2005-018725, PULMOTENSION). This
study has been approved by the local Ethics Committee
(Marburg Ref. 198/7).
RNA isolation and analysis by Affymetrix
Affymetrix analysis was performed at the University of
Munich, Microarray Resource Centre, according to an
established and approved protocol. Briefly, RNA was iso-
lated from frozen lung tissues using the NucleoSpin
RNA II kit from Macherey Nagel (Dueren, Germany),
and quality aspects, such as absorbency ratios, 28 S/18 S
ratios, and length of cDNA and cRNA synthesis pro-
ducts were assessed. Microarray hybridization probes
were synthesized from 5 μg total RNA according to themanufacturer`s instructions (Affymetrix, Santa Clara,
CA, USA). HumanHG-U133A Gene Chip arrays were
hybridized and stained according to the protocol provided
by Affymetrix. (http://www.mikrobio.med.tu-muenchen.
de/category/expression-core-facility/).
The Affymetrix MAS 5.0 Suite 4.0 (MAS 4.0) software
was used to calculate expression levels, fold change and
to assess the significance of differential expression. A
p-value < 0.05 was considered significant. Due to the
exploratory nature of the microarray experiments, mul-
tiple testing correction was not performed [9]. Based on
previous experiences, Affymetrix recommendations and
published literature [10-13] transcripts exhibiting over
2-fold change were classed as being differentially expressed
between ZZ and MM COPD samples. A further filtering
step was introduced by assessing for significance of
differential expression. The double filtered list [14] of
differentially expressed genes (|FC|≥ 2 and p-value≤ 0.05)
was further analysed using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) (http://
david.abcc.ncifcrf.gov/). Based on the gene expression pro-
files from a specific functional annotation cluster, the pair-
wise Euclidean distance between the COPD profiles was
calculated. The calculated distances were then visualized
using multidimensional scaling (MDS) [15].Lung and liver tissue analysis by RT-PCR
The formalin-fixed and paraffin-embedded tissue samples
(FFPE) were retrieved from the archives of the Institute
of Pathology of Hannover Medical School following
the requirements of the local Ethics Committee ap-
proval (Nr. 990–2011). We analysed surgical lung
explants sampled at the time of transplantation from
GOLD-4 MM COPD (n=3) and ZZ COPD patients
(n= 3), as well as liver biopsies from liver cirrhosis sub-
jects with (n= 4) and without (n= 6) ZZ AATD. Selected
tissue samples were (morphologically) matched to the
above MM and ZZ COPD subgroups as closely as possible
(Table 1A and B). In addition, we selected surgical lung
explants from ZZ emphysema cases treated with AAT
augmentation therapy (from 3 to 20 years; n = 11, age
52.5± 2.1 (SD) years) and non-treated with augmentation
therapy (n= 6, age 44.7± 5.3 (SD) years). Lung explants
from MM COPD cases (n= 6) served as a reference.Laser-assisted microdissection and RNA extraction
FFPE 5 μm thick tissue sections were mounted on a
poly-L-lysin-coated membrane attached to a special
metal frame. After deparaffinization and hemalum stain-
ing, the CellCut Plus system (MMI Molecular Machines
& Industries AG, Glattbrugg, Switzerland) was used for
laser-assisted microdissection of lung compartments: we
isolated sections of lung parenchyma that showed
Table 1 Patient characteristics
Variables MM COPD ZZ COPD
N=3 N=3
Mean± SD
A. Transplanted lung tissue used for Affymetrix analysis
Age (years) 57 ± 4.8 62 ± 2.3
Gender (male/female) 3/0 2/1
Ex-smoker 3 3
Gold stage IV IV
Mean pulmonary art. pressure (mmHg) 25 ±5.1 32 ±12
Cardiac Index () 3.1 ± 0.3 3.0 ± 0.1
GOT (ref < 35U/L) 32 ± 21.1 28 ± 5.0
GPT (ref <45U/L) 25 ± 16.2 29 ± 8.0
Inhaled steroid therapy 3 3
Augmentation therapy with AAT 0 0
B. Transplanted lung tissue used for RT-PCR analysis
Age (years) 53.7 ± 2.7 48.3 ± 1.3
Gender (male/female) 3/0 3/0
Ex-smoker 3 3
Gold stage IV IV
Mean pulmonary art. pressure (mmHg) n.d. 28 ± 2.8
Cardiac Index () n.d. n.d.
GOT (ref < 35U/L) 28 ±6.2 28.3 ± 3.4
GPT (ref <45U/L) 36.7 ± 10.2 33.3 ± 9.0
Inhaled steroid therapy 2 3
Augmentation therapy with AAT 0 0
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no-touch technique, essentially as described [16].
cDNA synthesis and pre-amplification
Complementary DNA of each sample was generated
using the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Foster City, CA, USA) and fol-
lowing the manufacturer’s protocol. Complementary
DNA was pre-amplified in 14 PCR cycles with target
gene-specific PCR primers, increasing the sensitivity of
the subsequent real-time PCR analysis several thousand-
fold (PreAmp Master Mix Kit, Applied Biosystems), as
reported [17,18].
Real-time PCR
The pre-amplified cDNA from microdissected speci-
mens was evaluated by real-time PCR (TaqMan 7500
Real-Time PCR system, Applied Biosystems, Carlsbad, CA,
USA). Quantification was performed in reactions contain-
ing pre-amplified cDNA, TaqMan Gene Expression Master
Mix and the individual TaqMan Gene Expression Assay
(both from Applied Biosystems). Target genes KLF9,
KLF10, ZNF165, SNAIL1 and DEFA1 were selected andanalysed, following the manufacturer’s protocol. For
negative controls, the cDNA was replaced by water
[19]. CT values were calculated by normalization to
the mean expression of three endogenous controls
(POLR2A, β-GUS and GAPDH) and converted into 2-ΔCT
values with Excel 8.0 (Microsoft, Redmond, WA, USA)
which were then statistically analysed using the
Mann–Whitney U test and Prism 5.0. Values ≤ 0.05
were considered as statistically significant. Expression
graphics were created using GraphPadPrism, version
5.0 (GraphPad Software, San Diego, CA, USA).
Results
Tissues from explanted lungs of end-stage ZZ AATD-
related COPD (n = 3) and non-AATD, MM COPD
(n = 3) were used for gene expression analysis by
Affymetrix. Detailed information about these patients
can be found in Table 1 A. All patients had severe
lung function impairment; however, none of the patients
was a current smoker at the time of surgery and no one
was treated with AAT augmentation therapy. Another co-
hort of lung specimens was used for laser-assisted micro-
dissection, RNA extraction and RT-PCR analysis. Lung
explants from MM COPD (n=3) and ZZ COPD (n=3)
have been matched to the group of the cases used in
Affymetrix analysis (Table 1 B). To avoid the regional
variability of gene expression, we sampled lung tissue,
several from central and peripheral regions. Liver biopsies
were obtained from liver cirrhosis patients: 6 without
[5 males and 1 female, mean age 56.8± 6.7 (SD)] and 4
with [males, mean age of 56.25± 6.9 (SD)] ZZ AATD.
Additional RT-PCR analysis of selected genes was per-
formed on surgical lung explants from end-stage ZZ em-
physema cases with (n= 11, age 52.5± 2.1 (SD) years) and
without AAT augmentation therapy (n= 6, age 44.7± 5.3
(SD) years).
Genes that distinguish MM and ZZ end-stage COPD
A total of 162 probe sets were found to be differentially
expressed (p-value≤ 0.05 and |FC| ≥2) between MM “nor-
mal” and ZZ AATD-related end-stage COPD. Of those,
134 genes were up-regulated in ZZ lung tissue, while 28
were down-regulated (Additional file 1: Table S1).
Notably, among the top 5 probe sets with highest expres-
sion values in ZZ versus MM lungs, we found defensin
alpha1, nuclear receptor subfamily 4, hemoglobin gamma,
and pentraxin-related gene. All these genes were previ-
ously associated with COPD [19-21].
Gene ontology enrichment and functional group analysis
Using functional enrichment analysis according to the
DAVID online resource [22], we identified functional groups
of genes from tissue expression, diseases and biological
processes (UP_TISSUE,GENETIC_ASSOCIATION_DB_
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more enriched (the most overrepresented) in ZZ versus
MM COPD. As listed in Additional file 2: Table S2, our
search for differential gene expression in end-stage
COPD tissue from ZZ subjects revealed a significant
overrepresentation of genes associated with specific tis-
sue: 30 (22.9%) liver (p= 0.006), 11 (8.4%) skeletal
muscle (p= 0.016), and 30 (22.9%) lung (p= 0.039). Ana-
lysis of disease-association, revealed a significantly
enriched number of genes involved in diabetes type 2
(p= 0.013), Parkinson’s disease (p= 0.015), Alzheimer`s
disease (p=0.033) and polyneuropathy vasculitis (p=0.033)
(Additional file 3: Table S3). Furthermore, among all differ-
entially expressed genes in ZZ versus MM COPD cases, 19
(14.5%, p <0.001) genes were classified for the biological
process of response to organic substance (GO:0010033), 20
(15.3%, p <0.001) genes were classified for the biological
process of regulation of cell proliferation (GO:0042127), 10
(7.6%, p< 0.001) genes were classified for the transmem-
brane receptor protein tyrosine kinase signalling pathway
(GO:0007167), 15 (11.5%, p < 0.001) genes were classi-
fied for the biological process of response to injury
(GO:0009611) and 12 (9.2%, p = 0.0013) genes were classi-
fied for the biological process of enzyme-linked receptor
protein signalling pathway (GO:0007167) (Additional file 4:
Table S4). The genes from the above-listed biological pro-
cesses (GO) are presented in Table 2.Clustering of the genes
Using functional annotation-based classification [22], we
found 6 functionally related subgroups of genes. One
subgroup perfectly segregated ZZ and MM COPD
patients (Figure 1A and B). This set of genes included
zinc finger protein 165, snail homolog 1 (Drosophila),
Krüppel-like factors 4 (gut), 9 and 10 (Table 3), and
DNA-binding transcriptional regulators that play diverse
roles during differentiation and development. Functional
similarity between the genes in the cluster is illustrated
in Figure 2.Table 2 GO Biological processes enriched in lung tissue of ZZ
Term
GO:0010033 ~ response to organic substance
GO:0042127 ~ regulation of cell proliferation
GO:0007169 ~ transmembrane receptor protein tyrosine kinase signaling path
GO:0009611 ~ response to wounding
GO:0007167 ~ enzyme linked receptor protein signaling pathway
GO:0008285 ~ negative regulation of cell proliferation
GO:0008283 ~ cell proliferation
GO:0050878 ~ regulation of body fluid levels
GO:0050817 ~ coagulationAnalysis of candidate genes by RT-PCR
Three candidate genes, KLF9, KLF10 and ZNF165, were
randomly selected for validation by using a real-time
PCR analysis in the 6 additional explanted COPD lungs
from GOLD IV cases with and without ZZ AATD.
Figure 3 verifies that the expression of KLF9 (33.7-fold,
p = 0.0286) and KLF10 (98.5-fold, p = 0.019) is signifi-
cantly higher in end-stage ZZ compared to MM COPD
lungs. The expression of ZNF165 was very low in all
analysed lung tissues but was higher by 50% (NS) in ZZ
than in MM cases. To further validate whether differen-
tial expression of these genes is linked to the ZZ AATD,
we analysed liver tissues from cirrhosis patients with and
without ZZ AATD. Both KLF9 (1.7-fold, p = 0.038) and
KLF10 (1.73-fold, p = 0.030) were found to be signifi-
cantly higher expressed in liver cirrhosis tissue from ZZ
compared to MM AAT (Figure 4). The relative expres-
sion levels of ZNF165 in the analysed samples were very
low or below detection limits (data not shown).
To further confirm our findings, lung tissue samples
obtained from ZZ COPD with and without augmenta-
tion therapy, were analysed for the expression of KLF9,
SNAIL1 and DEFA1. Remarkably, surgical lung explants
obtained from ZZ AAT deficiency-related emphysema
patients treated from 3 to 20 years with AAT augmenta-
tion therapy showed lower expression of these genes –
and did not differ significantly from MM specimens (Fig-
ure 5). Moreover, DEFA1 and SNAIL1 were found to be
significantly higher expressed in ZZ end-stage lungs as
compared to MM (n=6; 10.98-fold, p = 0.05 and 7.87-fold,
p = 0.01, respectively). KLF9 was also higher expressed in
ZZ (by 1.5-fold, NS) relative to MM COPD, although
these differences did not reached statistical significance.Discussion
To further explore lung tissue analysis using microar-
rays, we examined gene expression profiles in well
matched end-stage (GOLD IV) COPD cases with ZZ
AATD and without, “normal” MM COPD. Primarily, werelative to MM COPD
Gene number (%) P value
19 (14.5%) <0.0001
20 (15.3%) <0.0001








Figure 1 A: A cluster of functionally related genes, as found by DAVID functional annotation classification, perfectly segregates MM
and ZZ COPD samples. This separation is visualized here by multidimensional scaling (MDS). A: Based on the gene expression patterns of the
specific functional gene cluster, the pairwise Euclidean distance between the COPD samples is shown in a two-dimensional space. B: The
visualization from Figure 1 A is further supported by a heatmap depiction. This heat map shows the relative (z-score) expression level for each
gene and sample combination. A high expression level is associated with red, while green represents a low expression level.
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MM and ZZ end-stage COPD and secondly, we sought
for probable cluster(s) of genes which are able to strat-
ify COPD cases by the genetic variant of AAT. It is
important to point out that most patients with AATD-
related emphysema are treated with AAT augmentation
therapy. In order to make an appropriate match with
“normal” MM COPD, we included non-augmented
AATD cases which very much restricted the sample
size of our cohort. We therefore deliberately used dif-
ferent cohorts of COPD and liver cirrhosis patients for
the RT-PCR, because the replication of gene expres-
sion findings in a distinct cohort increases the likeli-
hood of these results being applicable to wider
populations of COPD patients.
Nevertheless, our results show that a relatively small
number of genes is significantly differently expressed
in end-stage ZZ lungs when compared to those from
MM. Remarkably, out of 162 gene sets differently
expressed between ZZ and MM-COPD lungs, 134
(82.7%) were up-regulated and only 28 (17.3%) were
down-regulated in ZZ lungs. It is worth pointing out
that among all up-regulated gene sets, the gene encod-
ing α1-defensin (DEFA1) was one of the most highly
(13-fold higher) expressed in ZZ compared to MMTable 3 Separating functional annotation group
Affymetrix –ID Gene name
202393_s_at Krüppel-like factor 10
206683_at zinc finger protein 165
220266_s_at Krüppel-like factor 4 (gut)
219480_at snail homolog 1 (Drosophil
203543_s_at, 203542_s_at Krüppel-like factor 9lung tissue. This finding was confirmed by RT-PCR
analysis and is in line with previous studies showing
that α-defensin concentrations are increased in indivi-
duals with AATD [23] and that patients with AATD
have a milieu where high concentrations of α-defensins
and low amounts of AAT potentiate the impact of α-
defensins on lung injury [24,25]. Remarkably, we could
further verify in different cohorts that the expression
of DEFA1 is higher in lungs from ZZ cases compared
to MM COPD specimens. Based on this latter finding,
we examined whether ZZ AAT deficiency-related em-
physema patients treated with ProlastinW had lower
DEFA1 expression in their lungs. Indeed, we found
that augmentation therapy lowers DEFA1 expression
when compared to untreated matched patients. Thus,
our discovery that AAT influences DEFA1 gene ex-
pression opens new possibilities to further optimize
augmentation therapies.
To our surprise, a set of genes including zinc finger
protein 165, snail homolog 1 (Drosophila), and Krüppel-
like transcription factors (KLFs) 4 (gut), 9 and 10, per-
fectly discriminated between patients with end-stage
“normal” MM and ZZ AATD–related COPD (Figures 1
and 2). Further conformation in a different cohort of





−3 (−2,77) 0,005 (0,02)
Figure 2 One functionally related gene cluster allowed for the separation between MM and ZZ COPD samples (Figure 1). The figure
shows the functional terms, based on which the genes of interest were grouped together. For each gene, membership of a functional group is
color coded. Green signifies membership, while black states that the gene in question does not belong to the particular functional group.
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expressed in ZZ relative to MM AAT subjects, allows us
to propose that the increased expression of zinc finger
transcription factors is related to AATD. To our know-
ledge, so far only one study has shown an enhancedFigure 3 mRNA expression of KLF9, KLF10 and ZNF165 in explanted l
MM COPD (n = 3). Expression of target genes was calculated using the Δ
median and percentiles, p-values indicate significance.expression (2.1-fold) of Krüppel-related zinc finger pro-
tein (specifically undefined) in lung tissue from patients
with AATD-associated emphysema when compared to
normal lung tissue [26] and it has been shown that
KLF4 mRNA is up-regulated more than 10-fold in miceung tissue of end-stage ZZ AATD-related (n = 3) and “normal”
CT-method (see Materials and Methods for details). Lines indicate
Figure 4 mRNA expression of KLF9 and KLF10 in cirrhotic livers with (n = 4) and without (n = 6) ZZ AATD. Expression of target genes was
calculated using the Δ CT-method (see Materials and Methods for details). Lines indicate median and percentiles, p-values indicate significance.
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tially identified as a primary transforming growth factor
beta (TGF-β)-inducible early gene in human osteoblasts
[23]. KLF10 gene expression in the liver is shown to be
regulated by glucose. This argues for a pleiotropic role
of KLF10 in cellular biology by integrating antiprolifera-
tive, endocrine, metabolic, and circadian signals. As a
matter of fact, genomic analysis of the liver in a trans-
genic mouse model with inducible expression of mutant
Z and normal M variant of AAT protein unveiled a
number of significantly more highly expressed genes in
Z mice as an indicative of a TGF-β effect (among others
KLF10) [28]. These data, together with our current find-
ings suggest that induction of KLF10 gene expression
might be specific for the ER stress state that is associated
with the intracellular accumulation of aggregated Z AAT



















Figure 5 Relative mRNA levels for selected genes in lung explants fro
to 20 years with AAT augmentation therapy compared to samples fro
See Methods for details on microdissection, RNA extraction and RT-PCR. BaKLFs are critical regulators of many physiological pro-
cesses and are involved in disorders such as cardiovascu-
lar disease, cancer, and inflammatory conditions. While
numerous zinc finger proteins are expressed in the lung,
only a few have been clearly implicated in lung homeo-
stasis and disease. A recent study by Bhattacharya and
co-workers [29] identified biomarker genes enriched in
functions related to DNA binding and regulation of
transcription which allow the prediction of disease in an
unrelated data set, generated from patients with severe
emphysema, with 97% accuracy. Although individual
biomarkers in this study have not been identified, it is
clearly shown that the selected genes include members
of zinc finger–binding domain containing proteins. The
patterns of KLF gene expression have not been consid-





ZZ treated with Prolastin (N=11)
**
m ZZ AAT deficiency-related emphysema patients treated from 3
m matched, but non-treated patients and MM COPD controls.
rs indicate the mean (SE), *p < 0.05 and **p < 0.01.
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Lungs with end-stage emphysema display decreases in
overall global gene expression, with pronounced increase
in transcripts encoding pro-inflammatory mediators,
immune-response proteins, and proteolytic enzymes.
Some of these differentially-expressed genes are specific-
ally linked to ZZ AATD-related emphysema. Results
from the current study revealed a subgroup of genes
from the zinc-finger family which perfectly segregated
ZZ and MM COPD patients. This finding not only
shows that these two types of emphysema can be distin-
guished from each other, but also provides a deeper
insight into the pathophysiological mechanisms of lung
emphysema with and without AATD.
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